CENTOGENE

CENTOGENE Guiding Precision Medicine. CENTOGENE - transforming genetic data into medical decisions.

We are one of the worldwide leaders in the field of early genetic diagnostics for rare hereditary diseases. A data repository of genetic data from over 115 countries gives us a unique access to epidemiological, clinical and genetic information on hereditary disorders, including oncogenetic indications. We focus exclusively on providing the highest quality, patient-centred service, verified by mult

iple international accreditations (ISO, CAP, CLIA), regular pharmaceutical audits and our outstanding short turn-around times for analysis. We believe our medical expertise is based on cutting-edge technologies including whole exome/genome sequencing, innovative biomarkers and continued R&D. Our mutation database (CentoMD®) is the world’s largest for rare genetic diseases and is pivotal to our high-quality diagnostic reporting and comprehensive medical interpretation. CENTOGENE is a key partner for many high-profile pharmaceutical companies who are active in the orphan drug development.

04/08/2026

No summer schedule. No summer closures.
Same hours, same days — your samples, our priority, all August.

Non-Invasive Prenatal Testing Portfolio Update – Now with CentoNIPT Expanded Expertise You Can TrustOur CentoNIPT portfo...
22/07/2026

Non-Invasive Prenatal Testing Portfolio Update – Now with CentoNIPT Expanded
 
Expertise You Can Trust
Our CentoNIPT portfolio continues to grow with the addition of CentoNIPT Expanded, offering broader prenatal screening to support informed clinical decision-making.
 
NEW: CentoNIPT Expanded now offers:
✅ Available for singleton and twin pregnancies
✅ Comprehensive screening for fetal chromosome aneuploidies across all chromosomes
✅ Detection of partial deletions and duplications of ≥ 7 Mb across all autosomes
✅ Optional fetal s*x reporting
✅ Optional reporting of s*x chromosome aneuploidies (SCAs)
 
By delivering expanded genomic insights from a simple maternal blood sample, CentoNIPT Expanded provides broader prenatal screening to help support informed clinical decision-making throughout pregnancy.
 
CentoNIPT is a fast and accurate non-invasive prenatal screening test that:
• Is performed on a single maternal blood sample
• Can be performed from 10 weeks of gestation
• Combines advanced next-generation sequencing (NGS) technology with high-quality medical reporting
• Screens for the most common fetal chromosomal abnormalities, including Trisomies 21, 18, and 13, as well as s*x chromosome aneuploidies (Monosomy X, XXY, ###, and XYY)
 

Exciting news!CENTOGENE has taken ownership of Pearl Medical Analysis Laboratory in Abu Dhabi, strengthening our commitm...
14/07/2026

Exciting news!

CENTOGENE has taken ownership of Pearl Medical Analysis Laboratory in Abu Dhabi, strengthening our commitment to expanding access to advanced reproductive and genetic testing across the Middle East.

Together, we’re making precision medicine and personalized genetic care more accessible for healthcare professionals, patients, and families.

07/07/2026

We’re excited to launch CentoBiome!

Visit our booth to discover our latest innovation, meet our team, and learn how CentoBiome can make a difference.

We look forward to seeing you at Booth

07/07/2026

Are you at ESHRE 2026?

Come and visit us at Booth and ask for more information about the third generation of PGT-A.

See you here!

06/07/2026

Deep genetic expertise now in Canada!

We’re pleased to introduce Alissa Magwood, our Country Manager for Canada.

Come and visit her at our booth

06/07/2026

Come and meet our team at CENTOGENE’s Booth C33.

We’re pleased to introduce Bruno Coprerski, our Chief Operations Officer for Brazil and LATAM.

Stop by to meet Bruno and discover the next generation of Embryo Aneuploidy Testing.

📢 Join CENTOGENE’s Upcoming Webinar | With precise diagnostics towards emerging therapies in Duchenne and Becker Muscula...
26/06/2026

📢 Join CENTOGENE’s Upcoming Webinar | With precise diagnostics towards emerging therapies in Duchenne and Becker Muscular Dystrophy

At CENTOGENE, we are committed to improving care for patients with Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) through advanced diagnostic solutions and close collaboration with pharmaceutical partners driving innovation in treatment development.

During the session, we will discuss:
🔹 Disease background: Understanding DMD and BMD
🔹 Precision diagnostics: The multiomic approach through patient cases
🔹 Pharma services: Supporting the entire drug development life cycle
🔹 Real-world impact: The role of precision medicine in emerging therapies

🎙 Speaker: Peter Bauer, Chief Medical and Genomic Officer
🎤 Moderator: Mario D’Alessandro, Global Head, Pharma Business

📅 8 July 2026
🕓 4:00–5:00 PM CET

Save your seat today and discover how precision diagnostics are helping shape the future of care and enabling access to emerging therapies for patients with Duchenne and Becker Muscular Dystrophy.

Today, on International Dravet Syndrome Awareness Day, we recognize the importance of increasing awareness and supportin...
23/06/2026

Today, on International Dravet Syndrome Awareness Day, we recognize the importance of increasing awareness and supporting earlier identification of complex neurodevelopmental conditions.

Timely and accurate diagnosis can play a critical role in helping patients and families access appropriate care and make informed decisions throughout their healthcare journey.

At CENTOGENE, we believe that scientific innovation and genomic insights have the potential to support better understanding and contribute to improving patient care across complex conditions.

Raising awareness is an important step toward enabling earlier action and better outcomes.

🧬 Some answers can’t be found in DNA alone.Behind every unresolved variant, there’s a patient still waiting. RNA sequenc...
10/06/2026

🧬 Some answers can’t be found in DNA alone.

Behind every unresolved variant, there’s a patient still waiting. RNA sequencing can change that.

Meet CentoRNA — functional evidence that goes beyond the genome.

✅ Up to 5 variants per test
✅ VUS & ambiguous results resolved
✅ 25 business days TAT

🔬Every variant tells a story. CentoRNA helps complete it.

RNAsequencing PatientFirst

Adresse

Am Strande 7
Rostock
18055

Telefon

+4938180113416

Webseite

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von CENTOGENE erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.

Service Kontaktieren

Nachricht an CENTOGENE senden:

Verknüpfungen

Teilen